Focused On-demand Library for Dynein axonemal intermediate chain 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UI46

UPID:

DNAI1_HUMAN

Alternative names:

Axonemal dynein intermediate chain 1

Alternative UPACC:

Q9UI46; B7Z7U1; Q5T8G7; Q8NHQ7; Q9UEZ8

Background:

Dynein axonemal intermediate chain 1, also known as Axonemal dynein intermediate chain 1, plays a crucial role in the dynein complex of respiratory cilia. This protein is pivotal for the proper function and structure of motile cilia, which are essential for respiratory health and fertility. Its involvement in ciliary movement underscores its significance in cellular and physiological processes.

Therapeutic significance:

The protein is directly linked to primary ciliary dyskinesia and Kartagener syndrome, diseases characterized by ciliary malfunction leading to respiratory infections, bronchiectasis, and reduced fertility. Understanding the role of Dynein axonemal intermediate chain 1 could open doors to potential therapeutic strategies for these conditions, highlighting its importance in medical research and drug discovery.